Antithymocyte globulin

Drug Profile

Antithymocyte globulin

Alternative Names: anti-thymocyte globulin; anti-thymocyte globulin (rabbit); Antithymocyte immunoglobulin; ATG; Polyclonal rabbit antithymocyte globulin; Rabbit antithymocyte globulin; Rabbit-ATG; rATG; Thymoglobulin; Thymoglobuline

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Genzyme Corporation; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi Genzyme; Sanofi Pasteur; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Bone marrow transplant rejection; Graft-versus-host disease; Liver transplant rejection; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II Myelodysplastic syndromes; Type 1 diabetes mellitus

Most Recent Events

  • 28 Jun 2017 Genzyme completes a phase II trial in Graft-versus-host disease in USA (IV) (NCT00709592)
  • 25 Apr 2017 Launched for Renal transplant rejection (Prevention) in USA (IV)
  • 24 Apr 2017 Registered for Renal transplant rejection (Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top